Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Japan Ethical Drug Sales Up 2.2% in November: Crecon
January 12, 2024
- Sawai Further Delays Manufacturing Start at Trust Pharmatech Unit
January 11, 2024
- Maruho Nabs Japan Rights to AOBiome’s Eczema Drug
January 11, 2024
- New LLP Coverage Rule Loathed by Off-Patent Drug Makers but Innovative Players Hail Reform
January 10, 2024
- FDA Rejects Astellas’ Gastric Cancer Med over Manufacturing Issues
January 10, 2024
- Shionogi, NTT Data to Build Distribution Platform for Digital Therapeutics
January 10, 2024
- Quake Causes Eye Drug Maker to Stop Shipments Except Refrigerated Meds
January 10, 2024
- MTX Detoxifying Agent Megludase Finally Available in Japan
January 10, 2024
- Leqembi Now Approved in China: Eisai/Biogen
January 10, 2024
- BioCryst Japan to First Focus on Orladeyo Promotion, Eager to Set Up Own Sales Team: Local Head
January 9, 2024
- Santen, Astellas, 3 More Firms Hit by Manufacturing Delays after Quake
January 9, 2024
- Organon Japan Gets Approval for Fertility Med Follistim after Re-Filing
January 9, 2024
- Trelegy Frontrunner in GP Promotion, Dayvigo Defends Title in HP List in October: Intage
January 9, 2024
- Boehringer Grabs Rights to Kyowa Kirin’s Fibro-Inflammatory Disease Drug
January 9, 2024
- US FDA Accepts Stelara Biosimilar for Review: Meiji
January 9, 2024
- Equa, Betanis and More Brands Gird for Generic Entry in 2024; Xarelto Contenders Too?
January 5, 2024
- After New Year’s Quake, Wholesalers See Challenges in Drug Delivery to North Part of Noto Peninsula
January 5, 2024
- Moderna Seeks Japan Nod for Pre-Filled Syringe Form of COVID Vaccine
January 5, 2024
- After GCP Scandal, Medipharma Begins Bankruptcy Proceedings
January 5, 2024
- Astellas, China Biotech Hook Up on Bispecific Macrophage Engagers
January 5, 2024
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…